OPERON ELEVATEPLUS | REGULATORY DUE DILIGENCE FOR MEDICAL DEVICES

Medical Device Due Diligence & Regulatory Consulting Services in Germany

Operon Strategist delivers structured regulatory due diligence services tailored for private equity, venture capital, and corporate acquirers evaluating medical technology assets in Germany and the wider European market. Our assessments go far beyond basic checklists, providing deep visibility into EU MDR/IVDR compliance maturity, technical file readiness, and hidden regulatory liabilities. By delivering decision-grade intelligence, we help investors uncover hidden operational gaps, protect their valuations, and execute strategic deals with total confidence.

Take the Next Step in Market Expansion

Connect with our regulatory experts to de-risk your investment, streamline EU MDR/IVDR compliance, or accelerate your German market access.

Operon ElevatePlus
Regulatory Due Diligence for Medical Devices Service Portfolio

Validation of device classification and intended use

Review of current and planned regulatory approval routes

Assessment of submission, approval, and commitment status

Identification of approval dependencies impacting deal timelines

Markets covered: US FDA, EU MDR/IVDR, UKCA, CDSCO, SFDA, and other global jurisdictions

Evaluation of technical documentation and dossier completeness

ISO 13485 and Quality Management System compliance assessment

Review of labeling, IFU, claims, and promotional compliance risks

Assessment of Post-Market Surveillance and vigilance obligations

Review of manufacturing licenses and site authorizations

QMS maturity assessment against certification scope

Inspection readiness analysis (FDA, Notified Body, CDSCO)

Review of audit observations, CAPAs, and open nonconformities

Identification of process validation and production control risks

Identification of comparable approved devices

Review of substantial equivalence and regulatory precedents

Competitive regulatory positioning and approval learnings

Review of clinical, performance, usability, and real-world data

Alignment with FDA, EU MDR/IVDR, and global evidence expectations

Identification of evidence gaps and post-market study risks

Classification of risks as critical, major, or manageable across performance, usability, and real-world data

Identification of regulatory non-compliance exposure

Approval dependency and enforcement risk evaluation

Estimation of remediation effort, cost, and timeline

Why Investors Choose Operon Strategist for MedTech M&A

Global exposure, structured thinking, and execution-ready expertise

Global Regulatory Expertise Across US, EU, UK, India, GCC & Emerging Markets

Coverage of Medical Devices & IVDs Across All Risk Classes (Class I, IIa, IIb, III & IVDs)

Experience Supporting Investment, M&A & Strategic Transactions

Proven Insights Aligned with Real-World Approvals & Inspections

Thorough medical device due diligence is essential to de-risking investments and M&A transactions within Europe’s strict regulatory climate. We support investors and target companies with comprehensive medical device regulatory due diligence and robust quality system due diligence to evaluate absolute market readiness. Each engagement provides a detailed due diligence report covering risk reclassifications, Notified Body audit history, and GSPR compliance. Crucially, we translate technical risks into direct impacts on valuation and transaction timelines, providing clear, actionable pre-close and post-close remediation roadmaps.

Operon Regulatory Due Diligence for Medical Devices Advantage

Identify hidden regulatory liabilities, technical file gaps, and compliance exposure before you invest, acquire, or partner—delivering decision-grade intelligence for European MedTech transactions

Independent, Execution-Neutral Regulatory Assessments

Translation of Regulatory Exposure into Business & Valuation Impact

Market-Wise, Approval-Focused Risk Visibility

Practical Remediation & Post-Transaction Planning Insights

frequently asked questions

An assessment evaluates the target asset’s entire compliance history. This includes verifying active CE certificates under EU MDR/IVDR, inspecting tech documentation, reviewing clinical data portfolios, analyzing open Corrective and Preventive Actions (CAPA), and evaluating post-market surveillance records to flag any hidden regulatory liabilities before closing.

A thorough quality system due diligence ensures that the target company’s manufacturing controls are fundamentally compliant with EN ISO 13485 and European market rules. Spotting hidden gaps in the quality process early prevents unexpected post-transaction remediation expenses, shields against Notified Body audit failures, and protects your underlying valuation.

The strict implementation of EU MDR (2017/745) and IVDR (2017/746) has significantly escalated risks for investors. Legacy devices now face much tougher clinical evidence rules and potential reclassification. Due diligence services map out exactly whether a target’s current portfolio can maintain market access under the new rules or if a costly technical rewrite will be required.

The final report translates complex technical and regulatory exposures into direct business impacts. It offers a structured risk matrix, isolates potential deal-breaking gaps, evaluates how compliance issues affect transaction timelines, and provides clear, actionable pre-close and post-close remediation plans.

Identify Hidden Regulatory Liabilities Before You Close

Speak with our MedTech due diligence experts

Please provide the following information and we’ll put you in touch with the right person.